Novo Holdings picks up injectables CDMO in push for single-use manufacturing tech

Josh Sullivan

For 25 years, Ritedose has been a CDMO that’s provided sterile, aseptic production of single-dose medication for more than 8 billion doses. Novo Holdings has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Holdings picks up injectables CDMO in push for single-use manufacturing tech

Josh Sullivan

Sign up to read this article for free.

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Beam shares results from seven patients who received gene-edited sickle cell therapy

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat

No­vo Hold­ings picks up in­jecta­bles CD­MO in push for sin­gle-use man­u­fac­tur­ing tech

Josh Sullivan

Sign up to read this article for free.

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Novo Holdings picks up injectables CDMO in push for single-use manufacturing tech

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Beam shares results from seven patients who received gene-edited sickle cell therapy

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat